This week in therapeutics

Indication	Target/marker/ pathway	Summary	Licensing status	Publication and contact information
Cancer				
Hematological malignancies	Janus kinase-2 (JAK2; JAK-2)	<p>Genotyping studies of primary myelofibrosis patients suggest that the JAK-2 mutation JAK2V617F could help predict survival time and guide treatment. Patients with low numbers of the JAK2V617F allele had shorter time to anemia and leukopenia and lower survival than patients with high numbers of the JAK2V617F allele. Next steps include developing JAK-2 inhibitors and diagnostic assays based on JAK2V617F allele burden.</p> <p>At least four companies have JAK-2 inhibitors in clinical development to treat hematological malignancies.</p> <p>SciBX 2(27); doi:10.1038/scibx.2009.1068 Published online July 16, 2009</p>	Findings unpatented; unavailable for licensing	<p>Guglielmelli, P. <i>et al. Blood</i>; published online June 24, 2009; doi:10.1182/blood-2009-04-216044 Contact: Alessandro M. Vannucchi, University of Florence and Tumor Institute of Tuscany, Florence, Italy e-mail: amvannucchi@unifi.it</p>